Astria Net Tangible Assets from 2010 to 2026
| ATXS Stock | USD 12.89 0.20 1.53% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 143.5 M | Current Value 150.7 M | Quarterly Volatility 55 M |
Check Astria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astria Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 41 M, Selling And Marketing Expenses of 1.6 M or Other Operating Expenses of 134.7 M, as well as many indicators such as Price To Sales Ratio of 51.69, Dividend Yield of 0.0 or PTB Ratio of 1.72. Astria financial statements analysis is a perfect complement when working with Astria Therapeutics Valuation or Volatility modules.
Astria | Net Tangible Assets | Build AI portfolio with Astria Stock |
Latest Astria Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Astria Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Astria Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Astria Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Astria Net Tangible Assets Regression Statistics
| Arithmetic Mean | 52,958,379 | |
| Geometric Mean | 30,843,204 | |
| Coefficient Of Variation | 103.76 | |
| Mean Deviation | 47,520,064 | |
| Median | 25,913,000 | |
| Standard Deviation | 54,951,719 | |
| Sample Variance | 3019.7T | |
| Range | 138.9M | |
| R-Value | 0.87 | |
| Mean Square Error | 795.1T | |
| R-Squared | 0.75 | |
| Slope | 9,443,828 | |
| Total Sum of Squares | 48315.1T |
Astria Net Tangible Assets History
About Astria Therapeutics Financial Statements
Astria Therapeutics shareholders use historical fundamental indicators, such as Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Astria Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Astria Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Astria Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 143.5 M | 150.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Astria Stock Analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.